Biora Therapeutics, Inc (BIOR) - Long-Term Debt to Capital Coefficient

Biora Therapeutics (BIOR) acts as a technological pioneer, developing an intelligent microcapsule system for targeted drug delivery in the gastrointestinal tract, as evidenced by massive R&D expenditures. Current price action, where the long-term debt-to-equity ratio is fixed at 0.00, links these innovations to the initiation of chronic intestinal inflammation therapy to minimize risks. Remaining in the pre-commercial stage, Biora Therapeutics avoids pricing conflicts by focusing on achieving success in clinical trials.

This indicator determines the dependence of Biora Therapeutics (BIOR) on long-term borrowings by comparing liabilities with maturities exceeding one year against equity. The metric identifies the stability of financial leverage and refinancing risks during periods of stagnation. By analyzing the long-term debt structure relative to equity, an investor assesses the ability of Biora Therapeutics (BIOR) to fund clinical developments without excessive credit pressure. For the biotech sector with a low environmental footprint, liquidity remains the priority over borrowed capital. The stability of this balance confirms the viability of the business model.